Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
Status:
WITHDRAWN
Trial end date:
2025-08-08
Target enrollment:
Participant gender:
Summary
A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.